Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
SystaMedic, Inc. manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units, showing a level of diversification in the company's prosecution efforts.
The busiest examiner for the portfolio is ENGLISH, CONNOR KENNEDY, who is responsible for 1 pending office action. Given the total count of 2 pending office actions, the workload is shared between the 2 distinct examiners. This distribution across 2 distinct art units suggests that the company's filings cover different technical aspects within the Biotechnology & Pharmaceuticals sector.
For practitioners, this profile indicates a broader engagement with the patent office than a portfolio with 1 pending office action. The involvement of the distinct examiners and their respective art units provides multiple paths for potential patent grants, reducing the company's reliance on any individual's discretion. This spread of activity may indicate a varied research and development focus across the technology area. The presence of 2 pending office actions allows for a robust prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ENGLISH, CONNOR KENNEDY | 1 | 60.0% | +51.3% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921532 | DRUG COMBINATIONS FOR INHIBITING INFECTIVITY OF INFLUENZA AND CORONA VIRUSES | ENGLISH, CONNOR KENNEDY | 79d |
| 17290510 | AUTOPHAGY ACTIVATORS AND INHIBITORS OF FERROPTOSIS FOR PREVENTING ACUTE RENAL FAILURE AND NEUROTOXCITY INDUCED BY CERTAIN ANTIBIOTICS | NOTTINGHAM, KYLE GREGORY | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17921532 | DRUG COMBINATIONS FOR INHIBITING INFECTIVITY OF INFLUENZA AND CORONA VIRUSES | ENGLISH, CONNOR KENNEDY | 1625 | §103 | Final Rejection | 79d | Pending | Oct 26, 2022 |
| 17290510 | AUTOPHAGY ACTIVATORS AND INHIBITORS OF FERROPTOSIS FOR PREVENTING ACUTE RENAL FAILURE AND NEUROTOXCITY INDUCED BY CERTAIN ANTIBIOTICS | NOTTINGHAM, KYLE GREGORY | 1621 | §103 | Non-Final OA | — | Pending | Apr 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial